cancer

a proton accelerator against cancer

by

At the Madrid hospital in Fuenlabrada they are building something that, from the outside, doesn’t look like much: a two-story building with three-meter-thick concrete walls, a roof that had to be opened with a crane, and foundations designed to support dozens of tons of machinery. Inside that bunker is kept one of the most valuable assets that Spanish public health has received in decades. That technological jewel that they protect with concrete is the proton accelerator donated by the Amancio Ortega Foundation: one of the ten latest generation machines that the founder of Inditex agreed to surrender to the public health system in October 2021 in a donation valued at 280 million euros. The objective is to install them in seven autonomous communities and transform the cancer treatment in Spain. A custom concrete bunker. Building this type of technology is not like installing a scanner or an X-ray device. The radiation emitted by a proton accelerator requires the construction of a specific building to act as a containment barrier. In Fuenlabrada that has become concrete walls three meters thick. The construction of the bunker began in July 2024 and the regional government has allocated 13 million euros to finance the construction of the new building. According to a statement of the Community of Madrid, the result is a two-story structure with more than 2,000 square meters of total surface area, partially connected to the already existing oncology area. The ground floor, of about 1,300 square meters, will house the diagnosis, treatment and patient preparation areas. The first floor, of 875 square meters, will be used for maintenance, supplies, medical offices and training. The pieces that entered through the roof. The proton therapy equipment is made up of two main elements, and both are already inside the bunker. The first is the Cyclotron, the device that generates and accelerates protons that are then used as “ammunition” against cancer cells. It measures eight meters tall and weighs almost 50 tons. To place it in place, it was necessary to open the roof of the building and use a heavy crane to install it inside the bunker. The second element is the Gantry, the rotating arm that directs the radiation towards the tumor with millimeter precision. This component exceeds 11 meters in height and reaches 75 tons in weight. Its complete rotation capacity is what allows the tumor to be attacked from any angle and reduce damage to healthy surrounding tissues. In this video The installation process of one of these machines in the New York Proton Center is shown, using a process very similar to that used in the Fuenlabrada hospital. Protons change the rules of the game. Proton therapy is not an improved version of conventional radiotherapy, but rather it works with high-energy proton beams capable of concentrating the impact exactly on the tumor and stopping there, without continuing to irradiate the tissues behind. This makes it an especially useful tool for treat hard-to-reach tumorssuch as brain tumors, on neckspinal cord, lung, ocular, sarcomas, etc., and for pediatric patients, where minimize side effects In the long term it is critical. Until now, in Spain there were only two centers with this technology, both private: the Hospital Quirón de Pozuelo de Alarcón and the Clínica Universidad de Navarra. Thanks to the donation from the Amancio Ortega Foundation10 new proton therapy centers will soon be inaugurated in public hospitals distributed throughout the national territory. A nuclear reactor in the basement. The arrival of the two main pieces does not mean that the equipment is ready to use. Only the main elements have been installed in place. Over the next 12 months, engineers will carry out the complete assembly of both components, their calibration and the commissioning of the accelerator. It is a process that involves continuous testing to check and monitor radiation before any patient is approached. In December 2025, the Nuclear Safety Council (CSN) already issued a favorable authorization, with conditions, for the radioactive facility of the hospital: an essential requirement before the unit can operate. It won’t be the first, but it adds up.. The one in Fuenlabrada will not be the first public health device of these characteristics to offer proton therapy treatments. The Galicia center, in Santiago de Compostela, is the most advanced in its installation and already has the Proteus One accelerator. In this case, two bunkers have been necessary (one for treatment and the other for research) and the first patients are expected to be treated at the end of 2026 or beginning of 2027, with capacity for 250 patients per year per room. The Madrid hospital, for its part, aims that its unit will be operational throughout the first quarter of 2027. In Xataka | Amancio Ortega: the billionaire who lives like a neighbor (except for private jets and superyachts) Image | GTRES, New York Proton Center

Pancreatic cancer is a silent killer. A new experimental therapy has managed to “intercept” it before it attacks

by

Pancreatic cancer is classically known as one of the most lethal and feared that exist because of how difficult it can be to treat in some cases and the high mortality rates. But this high mortality rate is not due to its aggressiveness from minute 0, but to its stealthy nature, making it when he shows his face With the first symptoms, the disease is already in a very advanced phase that makes treatment very difficult. It’s where to act. In this way, the objective of the researchers is precisely to try to advance the diagnosis as much as possible, since treatment in the initial phases of the disease can give great results. And this is exactly what a new study that focuses on the ‘cancer interception’ strategy suggests. This is something that researchers at the University of Pennsylvania have focused on, who have achieved a vitally important advance in mouse models. And the fact is that, instead of focusing on attacking the already formed pancreatic tumor of considerable size, they have directed their artillery against the microscopic precursor lesions, known as PanIN. Its foundation. This is something that can be reduced to literally putting out the fire when it is still just a small spark. And as the specialized media report, by removing these microscopic lesions precancerous diseases, researchers manage to stop the advance towards the dreaded pancreatic adenocarcinoma in mice, proposing a total paradigm shift in how we could face this disease. Genetics is key. Something that has been known for a long time is that there are people who have a genetic predisposition to suffer from this disease. Specifically, in more than 90% of cases, the mutation responsible for triggering the disease is found in a gene called KRAS. A gene that for decades was considered “unapproachable” by classical pharmacology and that acted as a great shield against the disease. However, medicine is advancing in leaps and bounds, and this study uses selective inhibitors for this gene with the aim of silencing it precisely in PanIN lesions. In this way, by neutralizing the growth signals that the KRAS gene gives to tumor cells, they cannot take the step to begin to spread throughout the body, which causes the most serious symptoms. Mice today, hope for tomorrow. Logically, we must put our feet on the ground, since we are dealing with a preclinical study. That is, the therapy has proven to be a resounding success in animal models, but there is still a long way to go until this therapy can be used in a human in a hospital, since it must be seen that the effect is similar in our organisms. However, this research fits perfectly with the new medical philosophy against pancreatic cancer. As highlighted by the National Cancer Research Center (CNIO) in his recent communicationsthe future undoubtedly involves knowing the personalized risk and ensuring that those people who are more likely to suffer from pancreatic cancer due to their genetics receive exhaustive screening to detect the disease in time and increase the probability of survival. Images | Bioscience Image Library In Xataka | A Spanish milestone against pancreatic cancer: we are one step closer to eradicating it but there is still a long way to go

an mRNA vaccine that reduced his dog’s cancer

by

Paul Conyngham is not a biologist. He is not a veterinarian either. He is an engineer from Sydney with almost two decades of experience in the field of data science and AI. In 2024, her dog Rosie received a terrible diagnosis: she had mast cell cancer, the most common skin cancer in dogs and practically untreatable with conventional methods. After trying everything, Conyngham decided to take an alternative path: opened ChatGPT and started asking him questions. ChatGPT as a starting point. OpenAI’s AI model acted as Conyngham’s research assistant. It helped him make a plan in a field he knew absolutely nothing about, and it was the chatbot that suggested he explore immunotherapy treatments. He also pointed out the existence of the Ramaciotti Center for Genomics at the University of New South Wales (UNSW), and there he began a fascinating journey. $3,000 to sequence a tumor. At that Conyngham research center got in touch with Associate Professor Martin Smith, one of its leaders. Conyngham paid $3,000 to sequence the DNA from Rosie’s tumor, which Smith found strange: They typically don’t support sequencing requested by individuals because interpreting the data is extraordinarily difficult. But Conyngham assured him that he had nothing to worry about and told him that he was a data analyst and that he would analyze them with the help of ChatGPT. From ChatGPT to AlphaFold. With that sequencing data in hand, Conyngham used a variety of AI tools—not just ChatGPT—to identify the relevant mutations. Then he went one step further and used AlphaFoldthe Google DeepMind program that predicts the three-dimensional structure of proteins. That allowed him to model which of those mutations could be driving the tumor. From this data he identified candidate drugs to help in the treatment of cancer and presented himself to the UNSW researchers with his homework done. First obstacle: bureaucracy. The research team identified an immunotherapy drug that seemed promising, but its manufacturer refused to supply it for this type of application. It was a hard blow for Conyngham, but then Smith told him about mRNA vaccines and asked him if he wanted to explore that avenue. Of course, said Conyngham. Actually manufacturing the vaccine was only half the problem, because administering it required ethical approval permission, which allows experiments involving living beings. After preparing a 100-page document over the next two months, Conyngham won that approval. Vaccines in two months. A division of UNSW led by Professor Pall Thordarson, manufactured the vaccine from the half-page formula that Conyngham had generated. They just needed to find someone to administer it, and that’s how Conyngham managed to contact Rachel Allavena, a professor of canine immunotherapy at the University of Queensland. He traveled ten hours with Rosie and showed up there for his first injection in December. The tumor reduced by half. Researchers from UNSW and the University of Queensland have confirmed that one of Rosie’s tumors had shrunk by half. Allavena explained how even the shine of her coat had also recovered and the dog seemed happier and healthier. Conyngham confirmed it: her dog was losing energy, but six weeks after treatment they were in a park and Rosie jumped the fence to chase a rabbit she had seen. But. Although the story is extraordinary, there is no total and miraculous cure here (at the moment). One of the tumors responded to the vaccine, but another larger one did not. Additionally there have been no controlled trials or sample size beyond one animal or long-term data. Conyngham himself commented how “I have no illusions that this is a cure, but I do believe that this treatment has bought Rosie significantly more time and quality of life.” And Conyngham is no ordinary. It is also important to note that Conyngham had a very special profile: his 17 years of experience in data science and machine learning (machine learning) were crucial for his research to move forward. His technical knowledge allowed AI to enter a field he didn’t know but could understand, and the chatbot and other tools accelerated the process. But those who finally made it possible were immunologists, RNA engineers and the veterinary oncologists who participated in the process. Does this work for other cases? Smith asked a logical question after this singular success. “Why aren’t we rolling this out for all humans with cancer?” The short answer is clear: clinical trials take years, cost hundreds of millions of dollars, and require clear evidence that in this case is simply null. One of his colleagues, David Thomas, is already working on similar treatments of mRNA for human patients, and believes that there is something revolutionary here: “what is striking is the idea of ​​citizen science where someone from the street with a technical profile can use their skills in the scientific process.” The second vaccine is already underway. What this process has shown is that it is possible to dramatically compress the time between the idea and the experimental treatment. Thordarson noted that what Conyngham did—generating an mRNA formula without biology training—demonstrates that AI is helping to democratize this process. In fact, the work is not over: UNSW is already working on the genetic sequencing of the tumor that did not respond to treatment and the objective is to design a second vaccine aimed precisely at treating said tumor. Image | Ed Oswalt In Xataka | What the AI ​​pioneers awarded today with the Nobel Prize say now about AI and its risks

We have been wondering for decades if being vegetarian prevents cancer. We already have a very clear answer

by

There is a endless diets in different parts of the world, conditioned largely by local society and culture, such as in Spain, where the Mediterranean dietwhich is varied. But the focus of the debate is on what is the best diet to maintain good health in the long term. And here the vegetarian diet has a lot to say. Giving answers. For years, we have known that reducing our consumption of processed meat is beneficial for our health, but a new macro study led by the University of Oxford has put compelling data on the table about how dietary choice directly impacts the risk of developing different types of cancer. The work published in the magazine British Journal of Cancer is consolidated as the further analysis performed to date on this topic. And it is no wonder, since researchers have been able to analyze the histories of 1.8 million women and men who participated in nine prospective studies across three continents. A shield. Until now, previous studies they were already pointing that vegetarians had a lower oncological risk, but there was not the necessary statistical power to refine the data and make this categorical statement. But this study has come to change this, since researchers reveal that vegetarians have a significantly lower risk of suffering from five types of cancer compared to people who eat meat regularly. Results. Obviously, there are many other factors that influence this matter such as weight or lifestyle, but even adjusting the data, a clear result has been seen, which is summarized in the following risk reductions: 31% lower risk of suffering from multiple myeloma. 28% lower risk of kidney cancer. 21% lower risk of pancreatic cancer. 12% lower risk of pancreatic cancer. 9% lower risk of breast cancer. But the curious thing about these data is that for ten other types of cancer studied, such as lung cancer in non-smokers, science has not found a significant difference. And this opens the door to seeing why this diet is so specific for specific cancers. The small print. Not everything is so positive with this diet, since the study has shown that vegetarians have almost double the risk of developing esophageal cancer compared to people who eat meat in their diet. Because? According to researchers, the benefits of a vegetarian diet in cancer are explained by the greater intake of fruits, vegetables, fiber and the absence of processed meats. But the fact that they have a higher risk of having esophageal cancer is related to the nutritional deficiencies that vegetarians may have. And the lack of certain exclusive or more present nutrients in foods of animal origin could be weakening the natural defenses of this tissue. The rest of the diets. In addition to the war that may exist between meat and vegetables, researchers wanted to go further to look at the rest of the diet. In this case, the pescetarianswho do not consume meat, but do consume fish and seafood, had a lower risk of developing breast, kidney and colon cancer. But when we talk about vegansis where there are certain important nuances, since it has been seen that they have a higher risk of suffering from colorectal cancer. However, the researchers themselves point out that there are still not enough statistical cases to accurately evaluate the impact of veganism on rarer cancers. The recommendations. Given this study, everything that had been done in oncology is maintained, since the norm is to prioritize whole grains, legumes, fruits and vegetables in the diet, limiting the consumption of red and processed meats. Although logically always ensuring that all nutritional needs are met and following medical advice. Images | amin ramezani In Xataka | Having a beer or a wine at 65 seems like a harmless indulgence. We have more and more evidence to the contrary.

why the next great revolution against cancer is to make it chronic

by

If we ask someone what the goal of cancer medicine is, the answer is almost automatic: cure itmake it disappear or win the war against this devastating disease. However, in molecular biology laboratories and advanced oncology consultations, the verb is changing, since we no longer speak of “eradicating” at all costs, but to contain. An idea that may be quite shocking, but which is proposed as the future of medicine. The idea. Douglas Hanahan, one of the most influential figures in modern biology and one of the great responsible of the hallmarks of cancerwhich are the hallmarks that define a tumor, has put this idea on the table. In this case, it points to a concept that clashes with our intuition, but fits with scientific data: cancer without disease. The idea is provocative, since it suggests that histologically malignant tumors are possible living off of us without killing us or affecting our quality of life. The objective is no longer the total elimination of the enemy and becomes something more pragmatic: keeping it under biological and clinical control so that the patient dies with the cancer, but not from the cancer. There is no cure. In a recent interview and in your updates of the Hallmarks of Cancer 2022, Hanahan insists that the complexity of cancer makes a universal cure unlikely. Instead, it proposes to understand what specific capacities sustain the tumor, such as evasion of the immune system, inflammation, replicative immortality… to selectively block them. In this way, it is not about destroying the entire tissue, but about converting a lethal process into an indolent one. This is what Hanahan calls “adaptive resistance”, since we assume that the tumor will try to look for new escape routes, and we will change the therapeutic strategy to block them, maintaining the tumor ecosystem within safety margins. It already happens. All of this is not a futuristic theory, but rather it is already happening on two very different fronts: the tumors that we decide not to touch and the aggressive tumors that we have learned to stop. Not trying is sometimes the best. The most literal example of “cancer without disease” is found in the prostate and thyroid. Here, diagnostic technology has advanced so much that we detect tumors that, biologically, would never have caused problems. In the case of prostate canceralmost half of low-risk tumors now enter active surveillance protocols. In this way, instead of operating or radiating (with the risk of impotence and incontinence that entails), doctors begin to monitor the mass. And the data, after 20 years of follow-up in large groups of people, are quite clear: cancer-specific mortality in these well-selected groups is less than 1%. In the clinic. With all this, the idea is that it is better to live with a controlled cancer than to pay the physical price of curing it, although logically, if it goes too far out of containment, the most correct thing is to try to eradicate it with the tools we have. In the case of papillary thyroid cancer We also have this same situation, since overdiagnosis has led to stopping aggressive surgery in favor of observing tumors that the body keeps at bay on its own. The new chronicity. Where the paradigm changes most dramatically is in advanced or metastatic cancer. Twenty years ago, a diagnosis of stage IV lung cancer or metastatic melanoma was almost invariably a short-term terminal sentence. Today, thanks to immunotherapy and targeted therapies, a new category of patient has been born: the “treatable but not curable.” With this strategy there are already different organizations, like the British NCRIwhich describe growing cohorts of patients living for years with the disease. In this case they have metastases, but they live a normal life with their jobs and trips while receiving chronic or intermittent treatments to contain the disease. But without staying on the road. Changing the rules. This new paradigm within oncology has forced changing the rules of the game in clinical trialssince the aim is no longer just for the tumor to disappear, but for prolonged stabilization. With regard to toxicity, the logic of “maximum tolerated dose” in chemotherapy (give medication until the patient can tolerate it) does not work if you are going to treat the patient for five years, since their quality of life with very aggressive chemotherapy will decrease each time. Right now, quality of life and low toxicity are prioritized with ‘milder’ medications to allow long-term treatment without major side effects. This is why cancer is beginning to resemble, in its management, diabetes or HIV: a chronic condition that requires lifelong medication, but that does not necessarily dictate the date of your death. Psychological problems. Logically, this model of ‘chronic cancer’ has its shadows. Medical literature warns, for example, that living with “dormant” or controlled cancer places an enormous mental burden on patients. Studies on active surveillance show that, for some patients, the anxiety of having a “ticking time bomb” inside worsens their quality of life more than the surgery itself. And each review consultation can mean a world to know if it has gone more or less. And more problems. In addition to this, you must know that not all of these diseases can become chronic, such as glioblastoma or pancreatic cancer, which continue to have an aggressive biology that, today, escapes this lazy control. But also, turning cancer into chronic is great news for the patient, but a titanic challenge for public health, since it implies treating more people, for more years, with very high-cost biological drugs. The summary. Hanahan’s “cancer without disease” is not giving up. It is accepting that, if we cannot eliminate the enemy, victory lies in keeping it at bay long enough for life to continue its course and even allow science to continue advancing. As mortality statistics suggest: more and more people are dying with cancer, but fewer people of cancer. And in that nuance lies an entire medical revolution. Images | National Cancer … Read more

Working in a nuclear power plant is not the best way to avoid cancer. Now it turns out that its waste also serves to cure it

by

If there is a terrifying and mainstream disease, it is cancer: after all, according to the WHOone in five people will develop it at some point in their life. Although in some cases the risk factors vary depending on the type of cancer, working in a nuclear power plant poses some riskas long as there is greater exposure to ionizing radiation, even if there are no accidents or more intense exposure through maintenance work. Paradoxically, the activity of nuclear power plants, which can cause cancer, also serves to generate the basis of the medicine to cure it. And we are not talking about a potentially distant study, but rather something that can already be materialized. In fact, the United Kingdom has already taken a step forward to transform some of its radioactive waste into anti-cancer medication. The world’s first lead-212 radiopharmaceutical ecosystem. Because in the UK they have closed an agreement between the public body Nuclear Decommissioning Authority and the biotechnology company Bicycle Therapeutics for which the latter will have 400 tons of reprocessed uranium to extract the valuable (for the medical industry) lead – 212 for 15 years. Behind Bicycle is Sir Greg Winter, co-founder of the company and winner of the Nobel Prize in Chemistry in 2018. This will provide them with the infrastructure to create the world’s first end-to-end lead-212 radiopharmaceutical ecosystem, from discovery to commercial supply. So explains it Mike Hannay, Chief Product and Supply Chain Officer at Bicycle Therapeutics. The benefits of lead – 212. Lead – 212 is an isotope used in therapeutic contexts thanks to its particular decay properties, so that it emits both alpha and beta particles. While the former provide high-energy, short-range cytotoxicity, the latter have a more extended range, targeting micro-metastasis. In a simplified way, this medically applicable isotope is essential for precision treatments against tumors resistant to other therapies. Thus, it carries radiation and acts directly on cancer cells to destroy tumors, minimizing the damage to the surrounding healthy tissue. This type of technique offers promising results in prostate cancers and neuroendocrine tumors of organs such as the intestine or pancreas. Extracting lead-212 is an arduous task. Converting the waste from nuclear power plants into cancer treatments seems like a fantastic idea for two reasons: because of the cure for cancer itself and the problem of dealing with radioactive waste, one of the great challenges faced by these energy industries, which have also explored other avenues such as take advantage of the remaining energy. But getting here has not been easy: the extraction process of this isotope has been carried out by the United Kingdom National Nuclear Laboratory (UKNNL) with a complex chemical process that requires the isolation of scandalously small quantities of the precursor material from the used nuclear fuel. Thus, first the Thorium-228 is extracted from the reprocessed uranium to later process it into Radium-224. It is then loaded into a lead-212 generator that has been custom-made for Bicycle Therapeutics’ needs by US company SpectronRx. This is a continuous regeneration, producing enough lead-212 to deliver tens of thousands of doses of precision therapy per year. The laboratory explains that the critical part is in the beginning: “The initial precursor material extracted is comparable to finding a single drop of water in an Olympic swimming pool.” From that minute amount, an even smaller fraction of lead-212 is separated. First discover the universe, then cure cancer. In addition to this unexpected use of nuclear power plant waste, in recent weeks a group of researchers from the University of York have evidenced in a study that the intense radiation captured in the beam absorbers of particle accelerators could be reused to produce materials used in cancer therapies. Those particle accelerators They are used, among other things, in experiments to discover the matter of which the universe is composed. In Xataka | The rarest element on Earth aims to cure cancer. And Europe is already accelerating its production In Xataka | We have been believing that bacteria are a weapon against tumors for 150 years. And finally we have discovered how Cover | Jakub Zerdzicki and Ivan S

The rarest element on Earth aims to cure cancer. And Europe is already accelerating its production

by

In the fight against cancer there are many ‘weapons’ that we have at our disposalsuch as chemotherapy or radiotherapy. The problem is that these are assimilated like bombing a city to destroy a single house: it is achieved, but with a lot of collateral damage. But this can be solved if We attack only what interests usin this case a tumor cell, and science points to one of the rarest elements on the planet as a candidate to achieve this. Where are we now. The goal of science is to find the most specific therapies possible so that they attack a tumor cell and not a healthy cell with the aim of reducing the adverse effects of the treatment and also being more effective. For this there are different options such as immunotherapy or the use of very specific antibodies, but there is still a long way to go. A particle. He astatinewhose name comes from the Greek astats (“unstable”), lives up to its name. It is the rarest natural element on Earth and disappears almost as soon as it is formed and that is very interesting to us. Especially a ‘version’ of this element which is At-211 which has a half-life of only 7.2 hours. But this instability is part of its magic. At-211 is what Texas A&M scientists call a “Goldilocks” isotope: perfect for the job. Its advantages. Currently, heto traditional radiation used in cancer treatments have a great impact on the body when traveling over long distances. But At-211 emits alpha particles, which is a heavy, slow-moving helium nucleus, which when emitted releases an enormous amount of energy, but can only travel a tiny distance, just the thickness of a few cells. This is crucial. Targeted Alpha Therapy involves “gluing” an atom of At-211 to a molecule (such as an antibody) designed to specifically seek out and bind to cancer cells. At-211 travels through the body, ignoring healthy cells, and when it finds its target, it anchors to the tumor and releases its alpha particle. The result is a localized and devastating explosion of energy, which irreversibly destroys the DNA of the cancer cell. But since the particle cannot travel any further, the healthy cell next to it will not be affected, making this an almost perfect killer. Your problem. At first glance everything seems great, but… Why don’t we use it? The answer lies in its availability, since it is impossible to mine astatine, since with a life of 7.2 hours the clock is running against it. The only way to obtain it is to create it artificially in a cyclotron, a particle accelerator. The process basically involves firing a beam of alpha particles at a Bismuth-209 target. Now the advance that has been achieved is to create a fully automated system to produce and ship the AT-211 as quickly as possible so that it can be used. In Europe. With this advance, which has been made in Texas, processing time is reduced and the safety of technicians who do not have to handle this substance increases. And while Texas A&M resolves supply in the US, Europe is making a move. The project Accelerate.EUfunded by the European Union, was launched at the end of 2024 with a clear objective: to create a robust and sustainable manufacturing and treatment infrastructure for At-211 throughout Europe. The project focuses on especially difficult-to-treat cancers, such as pancreas, breast and brain tumors (glioblastomas), demonstrating that this therapy is a global strategic priority. The future therefore lies in the possibility of using one isotope to illuminate the tumor and then using another to kill it, inaugurating authentic personalized nuclear medicine. Images | freepik In Xataka | The most unexpected treatment against cancer is LED light, and it is giving good results

The most unexpected treatment against cancer is LED light, and it is giving good results

by

Currently there are many research groups that have a very clear objective: find a cancer treatment that is effective, specific and above all safe. Something that can be really complex because of everything that cancer hides behind it, but science continues to give us good news. The last one comes from the University of Texas and the University of Porto which have developed a technique based on tin oxide nanoflakes (SnOx) and LEDs that allows cancer cells to be destroyed with precision. The current problem. The therapy par excellence today in the fight against cancer, without a doubt It’s chemotherapy and radiotherapy. The first of these has numerous problems that have been tried to be corrected, such as low specificity, that is, it attacks both cancer cells like the healthy ones. And this ultimately produces many side effects that can cause you to not continue with the treatment. This makes the goal of science to seek specificity and for the treatment to attack only cancer cells. This is something that is being tried to achieve with immunotherapy and techniques like CAR-T which ultimately is part of personalized medicine for each patient and which offers a very specific selection of the type of cell to destroy. But science has not stopped here. The discovery. One of the techniques that appears to be promising is photothermal therapy (PTT). The concept in this case is quite simple to understand: inject nanomaterials into a tumor and then heat them using light. This logically causes a localized increase in temperature, which selectively destroys the cancer cells that have been marked before. The problem until now was materials and light. Many photothermal therapies require high-powered lasers, which are expensive and can damage surrounding tissue. Now, a team of researchers from the University of Texas at Austin and the University of Porto have found the key to changing the rules of the game. A secret ingredient. The team has developed a new photothermal agent called nanoflakes that are made of tin oxide. After all, they are tiny sheets with a thickness of less than 20 nanometers and what is really ingenious is how they were manufactured. The really ingenious thing is how they made them. They started from a cheap and abundant material such as tin disulfide, which ironically is useless for photothermal therapy. In this way, through a ‘green’ and scalable process called electrochemical exfoliation with oxidation, which only uses aqueous media, they managed to transform the inactive tin disulfide into tin oxide that was already ready to fight cancer. And the light came. Once this material was available, all that was left was to expose it to the LED irradiation low-cost that emit infrared light at 810 nm. In this case we are talking about radiation that is very safe and does not damage healthy skin as can occur with radiotherapy, and it is also extremely cheap and accessible to everyone (even developing countries). Results. To test the effectiveness, researchers have tested cells in culture. The first thing they saw was that this treatment had no effect on healthy cells, that is, it did not destroy them. But the best comes when applying it to cancer cells results in a great reduction in the different colonies. Specifically, in skin cancer there was a 92% reduction in the viability of tumor cells, while in colorectal cancer this percentage dropped to 50%, but still maintained good results. And all thanks to an increase in temperature from 37 °C to 50 °C in 30 minutes that killed cancer cells. The future. This study not only presents a more efficient material, but validates its use with safer and more economical light sources. The researchers themselves point to the potential of LED systems for applications such as skin cancer treatment, which could theoretically be self-administered at home. This would be a great advantage for patients and would reduce the burden on health systems, although there is still a lot of research ahead to see if this therapy can be viable in a range that will surely not be less than 10 years. Images | National Cancer Institute Logan Voss In Xataka | Colon cancers are increasing alarmingly among young people. We have a suspect: sedentary lifestyle

“Guided missiles” are revolutionizing cancer treatment. And they are already giving results

by

Chemotherapy marked a great revolution in the treatment of different cancers despite its many problems in the nonspecificity of the ‘attack’ that caused healthy cells to also be affected by its effects. Although attempts have been made to increasingly specific chemotherapiesthe reality is that the next natural step in the evolution of the treatment It is immunotherapy, which is a field that continues to advance, giving us more and more joy in the fight against cancer. But there is a revolution that wants to go much further, and it is nothing more than taking all the good things that immunotherapy has with the high potency of chemotherapy. And this ‘cocktail’ has a name: immunoconjugates (ADC). The current problem. Traditional chemotherapies have been seen as a really aggressive treatment that generates a large number of side effects by attacking absolutely everything they encounter. This forces us to rethink the strategy. For this, it has been thought in immunotherapy Basically what it does is ‘wake up’ our natural defenses so that it can attack the tumor with its own tools. Something that It is personalized for each individual. by extracting, for example, their T lymphocytes to ‘reprogram’ them and make them fight against the tumor, which is nothing more than their own cells. But the next step requires this specificity with greater potency than the stimulated immune system can provide. And this forces us to look for new therapies that have a similar mechanism, although it goes further in the way of applying the drug to the target cells. And this is where we are in the fight against cancer. The goal of treatment. Precisely the future focuses on personalized treatments for each of the patients who have cancer in their body, without having to generalize with a drug for one type of tumor. This is achieved with treatments that are considered ‘remote-controlled missiles’ or ‘Trojan horses’ that promise greater specificity when attacking a tumor cell and leaving the body’s healthy cells ‘calm’. But always taking into account the particular characteristics of a person’s tumor. This is what is achieved with ADCs which are designed like a missile with lethal precision. Its mission is to deliver an explosive charge of chemotherapy into the tumor cell, largely ignoring healthy cells, and the results are promising in the early phases of research, demonstrating its great potential to cure more patients in the early stages. That’s how they work. The technology behind ADCs (Antibody-Drug Conjugates) is as elegant as it is powerful. It is made up of three key parts: The antibody that acts as the guidance system. A monoclonal antibody designed in a laboratory to search and fit like a key in a lock to specific proteins, a kind of “antennae” (receptors), which are found massively on the surface of tumor cells. And the point is that each tumor cell has different ‘antennas’ and that is why it is important to find the most suitable antibody. The payload, which we can assume is our ‘warhead’ which is a very powerful chemotherapy molecule and so toxic that it often cannot be administered in normal chemotherapy mode due to the large effects it has. So, here we are combining chemotherapy with immunotherapy. The linker. A mechanism that binds the antibody and the cargo so that it can travel ‘comfortably’ through the blood until it reaches its target tissue. The process is pure military strategy: the ADC travels through the body, the antibody detects its target (the cancer cell), anchors to it and the cell, deceived, absorbs it. Once inside, the linker breaks and releases the chemotherapy, annihilating the malignant cell from within and without affecting the ‘neighbors’. A before and after. At the congress of the European Society of Medical Oncology (ESMO 2025) without a doubt this treatment has been on the lips of many experts. And it is logical seeing the good results that have been reported in this regard. You just have to see a recent study published in the prestigious magazine New England Journal of Medicine that confirms that this ADC such as trastuzumab deruxtecan is more effective than conventional chemotherapy in cases of metastatic HER2+ breast cancer, showing improvements from 7 to almost 10 months without tumor progression. Another treatment, sacituzumab govitecan, also has shown important results before him triple negative breast cancerwhich is one of the most aggressive and could have the worst prognosis. The result is also very promising: an improvement in survival and quality of life. The hidden side. Like all cutting-edge technology, ADCs are not without challenges. They are not harmless. One of the geniuses behind these studies, the Spanish Javier Cortés pointed out to the side effects that could occur, mainly diarrhea and lowered defense. This made him have to point out that “in general, Trojan horses give a toxicity that, in relation to traditional chemotherapy, is usually somewhat better.” But there is also another front ahead: in some patients with this treatment the tumor continues to grow. The investigation now focuses on understanding it: The tumor cell receptors may mutate and are not the appropriate target, the chemo release mechanism within the cell may fail, or the tumor may simply be resistant to that particular chemo. The future. What is being targeted right now is the possibility of mixing ADCs with immunotherapy or even combining several ADCs with each other. But where things get more interesting is the possibility of loading these ‘Trojan horses’ with radioligands, that is, rradioactive dioisotopes to apply radiotherapy very selective on cancer cells. In this way, a wide range of possibilities open up for the treatment of cancer. Images | Angiola Harry National Cancer Institute In Xataka | Colon cancers are increasing alarmingly among young people. We have a suspect: sedentary lifestyle

A study has just correlated them with a higher risk of cancer

by

When we plan to lose weight, one of the first things we do is declare war on carbohydrates in the diet, reducing them as much as possible. All of this is conditioned on many occasions by the ‘advice’ that is seen on social networks in blogs, and which may have severe conditions as it was collected. in a published article in Nature Microbiology which suggests that this type of diet may end up increasing the risk of suffering from colorectal cancer. The study. Researchers conditioned by the increase in the number of people who decide to give up carbohydrates Because they relate it to weight gain, he wanted to test what was happening in a series of mice. In this way, an investigation was created with three different diets: a normal diet, one low in carbohydrates and another Western-style diet with a large amount of fat and carbohydrates. The result. After exposing the mice to these conditions, they analyzed their microbiota discovering a particular strain of E. coli bacteria, which was producing a toxin that damaged DNA called colibactin. A toxin that, in combination with a diet low in carbohydrates and soluble fiber, promotes the growth of polyps in the colon, which may be the first step to cancer. As recognized by the researcher himself, Alberto Martín, professor of immunology at the Temerty Faculty of Medicine of the University of Toronto, at first it was thought that colorectal cancer was caused by a combination of different factors like diet or genetics. But now a door is opening that means that a specific diet can lead to our bacteria enhancing the appearance of cancer. Because. Researchers found that a diet deficient in fiber increases inflammation of the intestine and alters the microbial community that reside here, that offer us many benefits and about which we are beginning to know more and more. Specifically, they focused on E. Coli that produces colibactin as we have discussed before, but what is really important here is that the mice fed a low-carbohydrate diet had a thinner layer of mucus that separates the intestinal microbes from the epithelial cells of the colon. A priori, this mucus barrier that we have in the digestive system acts as a layer of protection that allows bacteria not to come into direct contact with epithelial cells. But if this shield is thinner due to this poor diet, more colibactin can reach the colon cells directly and act as an epigenetic mechanism that alters their structure and drives the deregulation of the factors that control their cell cycle. But the researchers wanted to go a little further, by analyzing the effects on mice that had genetic mutations in their cells in the pathway responsible for repair damage that occurs in DNA. In this case the effect was very clear: the repair of these damages was not favored. This means that all the failures that are generated daily in our cells are not repaired or that the cell simply cannot enter apoptosis (programmed cell death) through these pathways. Something that adds ‘papers’ to have a cancer cell that gets out of control. Lynch syndrome. A genetic health problem which makes the patient have a greater chance of suffering from certain types of cancer, including colorectal cancer. All this due to mutations in genes that repair DNA, such as MLH1 and MSH2, among others. In this way, if a carbohydrate-deficient diet is added to these people who already have a higher probability of suffering from colon cancer, the effect of colibactin will increase these probabilities. That is why the findings made by researchers suggest that people with Lynch syndrome who harbor these colibactin-producing bacteria should avoid stopping carbohydrates so as not to increase the risk. They even suggest that they can take specific antibiotics for these colibactin-producing bacteria to further reduce the risk. Probiotics. With taking antibiotics, I’m sure that on more than one occasion you have been recommended to take probiotics in order to maintain the intestinal microbiota before the treatment. In this case, research suggests that a strain of E. coli called Nissle that produces colibactin is found in these probiotics, which makes us ask many questions about its effect on cancer. In this way, his laboratory is investigating whether long-term use of this probiotic is safe for people with Lynch syndrome or for those who follow a low-carbohydrate diet. The antidote. Given all this, the question is obligatory: how can I avoid this if I have to consume few carbohydrates? To this end, the study has been able to see a correlation between the increase in soluble fiber in the diet with a decrease in the levels of colibactin-producing E. Coli. This is something that translates into less interaction with DNA repair mechanisms and therefore a lower probability of suffering from cancer. “We supplemented fiber and saw that it reduced the effects of the low-carbohydrate diet (…) Now we are trying to find out which sources of fiber are most beneficial,” says Bhupesh Thakur, postdoctoral fellow and lead author of the study. A treatment. The goal right now is to try to counteract the increased risk of cancer due to this bacterial toxin. To this end, the use of inulin is being investigated, which has been seen to reduce the amount of E. coli, which produces colibactin, and improves intestinal health in high-risk people. A treatment that, as it could not be otherwise, is focused on the fiber itself, which will become the best ally in these situations. Images | engin akyurt National Cancer Institute In Xataka | Intermittent fasting is the fad diet. At least among scientists who study its effects on the microbiome

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.